ERA in Young Primary Infertile RIF Patients
ConditionRecurrent Implantation Failure
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18-35
SponsorShangHai Ji Ai Genetics & IVF Institute
About this trial
This study aims to evaluate the clinical efficacy of transcriptome-based endometrial receptivity analysis (tb-ERA) and investigate the molecular mechanisms of abnormal receptivity in young women with unexplained recurrent implantation failure (RIF).
Eligibility criteria
Qualifiers
RIF Cohort - 1. Age ≤ 35 years; BMI 18-25 kg/m².
≥ 3 failed transfers of high-quality embryos.
No history of spontaneous or FET-related pregnancy, including biochemical pregnancy (primary infertility).
Written informed consent provided.
Disqualifiers
Known factors associated with RIF, including: uterine anatomical abnormalities (malformations, adhesions, polyps, submucosal fibroids, adenomyosis) and hydrosalpinx
Endocrine disorders (PCOS, thyroid dysfunction, hyperprolactinemia)
Reproductive immunological abnormalities, thrombophilia and infectious factors, abnormal semen parameters,
Chromosomal abnormalities in either partner (planned PGT-SR) or monogenic disease (planned PGT-M).
Trial design
Treatments tested in this trial
- tb-ERA and personalized embryo transfer
Treatment groups
400 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov